Vol. 3 No. 5 (2023)
Health Technology Reviews

Bevacizumab for Platinum-Sensitive Recurrent Ovarian Cancer

Published May 15, 2023

Key Messages

  • It was not clear from the studies in this review whether bevacizumab plus chemotherapy does or does not improve overall survival compared to chemotherapy alone (or with placebo) for recurrent platinum-sensitive ovarian cancer.
  • Most studies in this review found that bevacizumab plus chemotherapy results in longer progression-free survival than chemotherapy alone (or with placebo) for recurrent platinum-sensitive ovarian cancer.
  • Most studies in this review found that bevacizumab plus chemotherapy had a more beneficial effect on treatment response than chemotherapy alone (or with placebo) for recurrent platinum-sensitive ovarian cancer.
  • There was no difference in quality of life, based on 1 randomized controlled trial, and no clear differences in adverse events reported between bevacizumab plus chemotherapy or chemotherapy alone (or with placebo).